Embryomic

The Embryomic proprietary test, PMT-BC, is based on 12 years of development data and utilises mass spectrometry (MALDI-ToF MS) to analyse recently fertilised embryos (blastocysts). The test of new blastocysts is calibrated/checked against thousands of digitally stored spectra/biomarkers and uploaded into a predictive algorithm. This patented (2020) algorithm identifies the most metabolically competent/viable embryo for IVF transfer (to mother) and will reduce IVF treatment cycles (time to pregnancy), costs and emotional stress for prospective parents.

Key highlights:

• IVF as a fertility treatment is growing globally in importance.
• Only 25-30% of IVF treatment cycles succeed.
• PMT-BC Test developed over 20 years of research with IVF clinics, subjecting 12,000 spent blastocysts(embryos) to MALDI-ToF mass spectrometry over 12 years and building a digital spectra library for use in predictive algorithm. 
• Patents granted in EU, UK and China
• Lab established 2024 in DCU Innovation Campus 
• Validation studies of PMT-BC have started at a large Irish IVF Clinic chain, SIMS, and has received ethics approval from its parent company in Australia.
• Progress is being made with a German clinic to participate in a parallel validation study.